Addressing Critical Infectious Disease Threats with Targeted Monoclonal Antibody Immunotherapies


 

 

Our current monoclonal antibody programs address specific bacterial and viral pathogens. Our Phase 2 program, ASN100, selectively targets Staphylococcus aureus virulence rather than directly killing the bacteria, potentially allowing Arsanis to combat critical infections without contributing to antibiotic resistance or damaging the patient’s microbiome.


featured news